Basic immunosuppressive drugs outside solid organ transplantation

Bibliography

• DENTON MD, MAGEE CC, SAYEGH MH: Immunosuppressive strategies in transplantation. Lancet (1999) 353(9158):1083-1091.
   Google Scholar
• JORGA A, JOHNSTON A: Novel therapies in transplantation. Expert Opin. Investig. Drugs (2005) 14(3):295-304.
   PubMed Web of Science ®Google Scholar
• KORNBLUTH A, SACHAR DB: Ulcerative colitis practice guidelines in adults. American College of Gastroenterology, Practice Parameters Committee. Am. J. Gastroenterol. (1997) 92(2):204-211.
   PubMed Web of Science ®Google Scholar
• HANAUER SB, PRESENT DH: The state of the art in the management of inflammatory bowel disease. Rev. Gastroenterol. Disord. (2003) 3(2):81-92.
   PubMedGoogle Scholar
• LOFTUS CG, LOFTUS EV Jr, SANDBORN WJ: Cyclosporin for refractory ulcerative colitis. Gut (2003) 52(2):172-173.
   PubMed Web of Science ®Google Scholar
• SANDBORN WJ: Cyclosporine in ulcerative colitis: state of the art. Acta Gastroenterol. Belg. (2001) 64(2):201-204.
   PubMed Web of Science ®Google Scholar
• D’HAENS G, LEMMENS L, GEBOES K et al.: Intravenous cyclosporine versus intravenous corticosteroids as single therapy for severe attacks of ulcerative colitis. Gastroenterology (2001) 120(6):1323-1329.
   PubMed Web of Science ®Google Scholar
• SHIBOLET O, REGUSHEVSKAYA E, BREZIS M, SOARES-WEISER K: Cyclosporine A for induction of remission in severe ulcerative colitis. Cochrane Database Syst. Rev. (2005) 1:CD004277.
   PubMedGoogle Scholar
• MARSH JW, VEHE KL, WHITE HM: Immunosuppressants. Gastroenterol. Clin. North Am. (1992) 21(3):679-693.
   PubMed Web of Science ®Google Scholar
• HAWTHORNE AB: Ciclosporin and refractory colitis. Eur. J. Gastroenterol. Hepatol. (2003) 15(3):239-244.
   PubMed Web of Science ®Google Scholar
• VAN ASSCHE G, D’HAENS G, NOMAN M et al.: Randomized, double-blind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitis. Gastroenterology (2003) 125(4):1025-1031.
   PubMed Web of Science ®Google Scholar
• MUELLER EA, KOVARIK JM, VAN BREE JB, TETZLOFF W, GREVEL J, KUTZ K: Improved dose linearity of cyclosporine pharmacokinetics from a microemulsion formulation. Pharm. Res. (1994) 11(2):301-304.
   PubMed Web of Science ®Google Scholar
• LATTERI M, ANGELONI G, SILVERI NG, MANNA R, GASBARRINI G, NAVARRA P: Pharmacokinetics of cyclosporin microemulsion in patients with inflammatory bowel disease. Clin. Pharmacokinet. (2001) 40(6):473-483.
   PubMed Web of Science ®Google Scholar
• NAVAZO L, SALATA H, MORALES S et al.: Oral microemulsion cyclosporine in the treatment of steroid-refractory attacks of ulcerative and indeterminate colitis. Scand. J. Gastroenterol. (2001) 36(6):610-614.
   PubMed Web of Science ®Google Scholar
• ACTIS GC, LAGGET M, RIZZETTO M et al.: Long-term efficacy of oral microemulsion cyclosporin for refractory ulcerative colitis. Minerva Med. (2004) 95(1):65-70.
   PubMedGoogle Scholar
• ORTIZ V, NOS P, AGUILERA V, BERENGUER J, PONCE J: [Cyclosporin in an oral microemulsion as the initial treatment of corticoid-refractory ulcerative colitis]. Gastroenterol. Hepatol. (2000) 23(3):120-122.
   PubMedGoogle Scholar
• BOUSVAROS A, KIRSCHNER BS, WERLIN SL et al.: Oral tacrolimus treatment of severe colitis in children. J. Pediatr. (2000) 137(6):794-799.
   PubMed Web of Science ®Google Scholar
• FELLERMANN K, RUDOLPH B, WITTHOFT T et al.: [Sweet syndrome and erythema nodosum in ulcerative colitis, refractory to steroids: successful treatment with tacrolimus]. Med. Klin. (Munich) (2001) 96(2):105-108.
   PubMed Web of Science ®Google Scholar
• MATSUHASHI N, NAKAJIMA A, WATANABE K et al.: Tacrolimus in corticosteroid-resistant ulcerative colitis. J. Gastroenterol. (2000) 35(8):635-640.
   PubMed Web of Science ®Google Scholar
• FELLERMANN K, TANKO Z, HERRLINGER KR et al.: Response of refractory colitis to intravenous or oral tacrolimus (FK506). Inflamm. Bowel Dis. (2002) 8(5):317-324.
   PubMed Web of Science ®Google Scholar
• BAUMGART DC, WIEDENMANN B, DIGNASS AU: Rescue therapy with tacrolimus is effective in patients with severe and refractory inflammatory bowel disease. Aliment. Pharmacol. Ther. (2003) 17(10):1273-1281.
   PubMed Web of Science ®Google Scholar
• ORTH T, PETERS M, SCHLAAK JF et al.: Mycophenolate mofetil versus azathioprine in patients with chronic active ulcerative colitis: a 12-month pilot study. Am. J. Gastroenterol. (2000) 95(5):1201-1207.
   PubMed Web of Science ®Google Scholar
• SKELLY MM, LOGAN RF, JENKINS D, MAHIDA YR, HAWKEY CJ: Toxicity of mycophenolate mofetil in patients with inflammatory bowel disease. Inflamm. Bowel Dis. (2002) 8(2):93-97.
   PubMed Web of Science ®Google Scholar
• PROBERT CS, HEARING SD, SCHREIBER S et al.: Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial. Gut (2003) 52(7):998-1002.
   PubMed Web of Science ®Google Scholar
• GORNET JM, COUVE S, HASSANI Z et al.: Infliximab for refractory ulcerative colitis or indeterminate colitis: an open-label multicentre study. Aliment. Pharmacol. Ther. (2003) 18(2):175-181.
   PubMed Web of Science ®Google Scholar
• OCHSENKUHN T, SACKMANN M, GOKE B: Infliximab for acute, not steroid-refractory ulcerative colitis: a randomized pilot study. Eur. J. Gastroenterol. Hepatol. (2004) 16(11):1167-1171.
   PubMed Web of Science ®Google Scholar
• ARMUZZI A, DE PASCALIS B, LUPASCU A et al.: Infliximab in the treatment of steroid-dependent ulcerative colitis. Eur. Rev. Med. Pharmacol. Sci. (2004) 8(5):231-233.
   PubMedGoogle Scholar
• JARNEROT G, HERTERVIG E, FRIIS-LIBY I et al.: Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology (2005) 128(7):1805-1811.
   PubMed Web of Science ®Google Scholar
• WOLLINA U: Clinical management of pyoderma gangrenosum. Am. J. Clin. Dermatol. (2002) 3(3):149-158.
   PubMedGoogle Scholar
• KHURRUM BM, MARQUEZ H, NOGUERAS JJ, WEISS EG, WEXNER SD: Topical tacrolimus (FK506) in the treatment of recalcitrant parastomal pyoderma gangrenosum associated with Crohn’s disease: report of two cases. Colorectal Dis. (2004) 6(4):250-253.
   PubMedGoogle Scholar
• SHELDON DG, SAWCHUK LL, KOZAREK RA, THIRLBY RC: Twenty cases of peristomal pyoderma gangrenosum: diagnostic implications and management. Arch. Surg. (2000) 135(5):564-568.
   PubMed Web of Science ®Google Scholar
• HUGHES AP, JACKSON JM, CALLEN JP: Clinical features and treatment of peristomal pyoderma gangrenosum. J. Am. Med. Assoc. (2000) 284(12):1546-1548.
   PubMed Web of Science ®Google Scholar
• FRIEDMAN S, MARION JF, SCHERL E, RUBIN PH, PRESENT DH: Intravenous cyclosporine in refractory pyoderma gangrenosum complicating inflammatory bowel disease. Inflamm. Bowel Dis. (2001) 7(1):1-7.
   PubMed Web of Science ®Google Scholar
• GETTLER S, ROTHE M, GRIN C, GRANT-KELS J: Optimal treatment of pyoderma gangrenosum. Am. J. Clin. Dermatol. (2003) 4(9):597-608.
   PubMed Web of Science ®Google Scholar
• VIDAL D, PUIG L, GILABERTE M, ALOMAR A: Review of 26 cases of classical pyoderma gangrenosum: clinical and therapeutic features. J. Dermatol. Treat. (2004) 15(3):146-152.
   PubMedGoogle Scholar
• BAUMGART DC, WIEDENMANN B, DIGNASS AU: Successful therapy of refractory pyoderma gangrenosum and periorbital phlegmona with tacrolimus (FK506) in ulcerative colitis. Inflamm. Bowel Dis. (2004) 10(4):421-424.
   PubMed Web of Science ®Google Scholar
• DECKERS-KOCKEN JM, PASMANS SG: Successful tacrolimus (FK506) therapy in a child with pyoderma gangrenosum. Arch. Dis. Child. (2005) 90(5):531.
   PubMed Web of Science ®Google Scholar
• D’INCA R, FAGIUOLI S, STURNIOLO GC: Tacrolimus to treat pyoderma gangrenosum resistant to cyclosporine. Ann. Intern. Med. (1998) 128(9):783-784.
   PubMedGoogle Scholar
• GILMOUR E, STEWART DG: Severe recalcitrant pyoderma gangrenosum responding to a combination of mycophenolate mofetil with cyclosporin and complicated by a mononeuritis. Br. J. Dermatol. (2001) 144(2):397-400.
   PubMed Web of Science ®Google Scholar
• LEVY C, TREMAINE WJ: Management of internal fistulas in Crohn’s disease. Inflamm. Bowel Dis. (2002) 8(2):106-111.
   PubMed Web of Science ®Google Scholar
• LICHTENSTEIN GR: Approach to corticosteroid-dependent and corticosteroid-refractory Crohn’s disease. Inflamm. Bowel Dis. (2001) 7(Suppl. 1):S23-S29.
   PubMed Web of Science ®Google Scholar
• CINO M, GREENBERG GR: Bone mineral density in Crohn’s disease: a longitudinal study of budesonide, prednisone, and nonsteroid therapy. Am. J. Gastroenterol. (2002) 97(4):915-921.
   PubMed Web of Science ®Google Scholar
• SUTHERLAND L, SINGLETON J, SESSIONS J et al.: Double blind, placebo controlled trial of metronidazole in Crohn’s disease. Gut (1991) 32(9):1071-1075.
   PubMed Web of Science ®Google Scholar
• PRANTERA C, BERTO E, SCRIBANO ML, FALASCO G: Use of antibiotics in the treatment of active Crohn’s disease: experience with metronidazole and ciprofloxacin. Ital. J. Gastroenterol. Hepatol. (1998) 30(6):602-606.
   PubMed Web of Science ®Google Scholar
• CARTER MJ, LOBO AJ, TRAVIS SP: Guidelines for the management of inflammatory bowel disease in adults. Gut (2004) 53(Suppl. 5):V1-V16.
   PubMed Web of Science ®Google Scholar
• McDONALD J, FEAGAN B, JEWELL D, BRYNSKOV J, STANGE E, MacDONALD J: Cyclosporine for induction of remission in Crohn’s disease. Cochrane Database Syst. Rev. (2005) 2:CD000297.
   PubMedGoogle Scholar
• BRYNSKOV J, FREUND L, RASMUSSEN SN et al.: A placebo-controlled, double-blind, randomized trial of cyclosporine therapy in active chronic Crohn’s disease. N. Engl. J. Med. (1989) 321(13):845-850.
   PubMed Web of Science ®Google Scholar
• SANDBORN WJ: Preliminary report on the use of oral tacrolimus (FK506) in the treatment of complicated proximal small bowel and fistulizing Crohn’s disease. Am. J. Gastroenterol. (1997) 92(5):876-879.
   PubMed Web of Science ®Google Scholar
• SANDBORN WJ, PRESENT DH, ISAACS KL et al.: Tacrolimus for the treatment of fistulas in patients with Crohn’s disease: a randomized, placebo-controlled trial. Gastroenterology (2003) 125(2):380-388.
   PubMed Web of Science ®Google Scholar
• LOWRY PW, WEAVER AL, TREMAINE WJ, SANDBORN WJ: Combination therapy with oral tacrolimus (FK506) and azathioprine or 6-mercaptopurine for treatment-refractory Crohn’s disease perianal fistulae. Inflamm. Bowel Dis. (1999) 5(4):239-245.
   PubMed Web of Science ®Google Scholar
• IERARDI E, PRINCIPI M, FRANCAVILLA R et al.: Oral tacrolimus long-term therapy in patients with Crohn’s disease and steroid resistance. Aliment. Pharmacol. Ther. (2001) 15(3):371-377.
   PubMed Web of Science ®Google Scholar
• BOUSVAROS A, LEICHTNER AM, BOOK L et al.: Treatment of pediatric autoimmune enteropathy with tacrolimus (FK506). Gastroenterology (1996) 111(1):237-243.
   PubMed Web of Science ®Google Scholar
• PASCU M, MULLER AR, WIEDENMANN B, DIGNASS AU: Rescue therapy with tacrolimus in a patient with toxic megacolon. Int. J. Colorectal Dis. (2003) 18(3):271-275.
   PubMed Web of Science ®Google Scholar
• MIEHSLER W, REINISCH W, MOSER G, GANGL A, VOGELSANG H: Is mycophenolate mofetil an effective alternative in azathioprine-intolerant patients with chronic active Crohn’s disease? Am. J. Gastroenterol. (2001) 96(3):782-787.
   PubMed Web of Science ®Google Scholar
• FICKERT P, HINTERLEITNER TA, WENZL HH, AICHBICHLER BW, PETRITSCH W: Mycophenolate mofetil in patients with Crohn’s disease. Am. J. Gastroenterol. (1998) 93(12):2529-2532.
   PubMed Web of Science ®Google Scholar
• NEURATH MF, WANITSCHKE R, PETERS M, KRUMMENAUER F, MEYER ZUM BUSCHENFELDE KH, SCHLAAK JF: Randomised trial of mycophenolate mofetil versus azathioprine for treatment of chronic active Crohn’s disease. Gut (1999) 44(5):625-628.
   PubMed Web of Science ®Google Scholar
• WENZL HH, HINTERLEITNER TA, AICHBICHLER BW, FICKERT P, PETRITSCH W: Mycophenolate mofetil for Crohn’s disease: short-term efficacy and long-term outcome. Aliment. Pharmacol. Ther. (2004) 19(4):427-434.
   PubMed Web of Science ®Google Scholar
• FELLERMANN K, STEFFEN M, STEIN J et al.: Mycophenolate mofetil: lack of efficacy in chronic active inflammatory bowel disease. Aliment. Pharmacol. Ther. (2000) 14(2):171-176.
   PubMed Web of Science ®Google Scholar
• FORD AC, TOWLER RJ, MOAYYEDI P, CHALMERS DM, AXON AT: Mycophenolate mofetil in refractory inflammatory bowel disease. Aliment. Pharmacol. Ther. (2003) 17(11):1365-1369.
   PubMed Web of Science ®Google Scholar
• RUIZ-IRASTORZA G, KHAMASHTA MA, HUGHES GR: Therapy of systemic lupus erythematosus: new agents and new evidence. Expert Opin. Investig. Drugs (2000) 9(7):1581-1593.
   PubMed Web of Science ®Google Scholar
• KUIPER-GEERTSMA DG, DERKSEN RH: Newer drugs for the treatment of lupus nephritis. Drugs (2003) 63(2):167-180.
   PubMed Web of Science ®Google Scholar
• WARNER LM, ADAMS LM, SEHGAL SN: Rapamycin prolongs survival and arrests pathophysiologic changes in murine systemic lupus erythematosus. Arthritis Rheum. (1994) 37(2):289-297.
   PubMed Web of Science ®Google Scholar
• FURST DE: Leflunomide, mycophenolic acid and matrix metalloproteinase inhibitors. Rheumatology (Oxford) (1999) 38(Suppl. 2):14-18.
   PubMed Web of Science ®Google Scholar
• KREUTER A, GAMBICHLER T, BREUCKMANN F et al.: Pimecrolimus 1% cream for cutaneous lupus erythematosus. J. Am. Acad. Dermatol. (2004) 51(3):407-410.
   PubMed Web of Science ®Google Scholar
• LAMPROPOULOS CE, SANGLE S, HARRISON P, HUGHES GR, D’CRUZ DP: Topical tacrolimus therapy of resistant cutaneous lesions in lupus erythematosus: a possible alternative. Rheumatology (Oxford) (2004) 43(11):1383-1385.
   PubMed Web of Science ®Google Scholar
• GRIFFITHS B, EMERY P: The treatment of lupus with cyclosporin A. Lupus (2001) 10(3):165-170.
   PubMed Web of Science ®Google Scholar
• MORTON SJ, POWELL RJ: An audit of cyclosporin for systemic lupus erythematosus and related overlap syndromes: limitations of its use. Ann. Rheum. Dis. (2000) 59(6):487-489.
   PubMed Web of Science ®Google Scholar
• MANGER K, KALDEN JR, MANGER B: Cyclosporin A in the treatment of systemic lupus erythematosus: results of an open clinical study. Br. J. Rheumatol. (1996) 35(7):669-675.
   PubMedGoogle Scholar
• SCHIEL R, BAMBAUER R: Therapeutic plasma exchange and cyclosporine in the treatment of systemic lupus erythematosus. Ther. Apher. (1999) 3(3):234-239.
   PubMedGoogle Scholar
• SCHIEL R, BAMBAUER R, LATZA R, KLINKMANN J: Cyclosporine and therapeutic plasma exchange in treatment of progressive autoimmune diseases. Artif. Organs (1997) 21(9):983-988.
   PubMed Web of Science ®Google Scholar
• DAMMACCO F, DELLA CASA AO, FERRACCIOLI G, RACANELLI V, CASATTA L, BARTOLI E: Cyclosporine-A plus steroids versus steroids alone in the 12-month treatment of systemic lupus erythematosus. Int. J. Clin. Lab. Res. (2000) 30(2):67-73.
   PubMedGoogle Scholar
• CONTI F, PRIORI R, ALESSANDRI C, SPINELLI FR, MEDDA E, VALESINI G: Safety profile and causes of withdrawal due to adverse events in systemic lupus erythematosus patients treated long-term with cyclosporine A. Lupus (2000) 9(9):676-680.
   PubMed Web of Science ®Google Scholar
• FEUTREN G, QUERIN S, NOEL LH et al.: Effects of cyclosporine in severe systemic lupus erythematosus. J. Pediatr. (1987) 111(6 Part 2):1063-1068.
   PubMed Web of Science ®Google Scholar
• CACCAVO D, LAGANA B, MITTERHOFER AP et al.: Long-term treatment of systemic lupus erythematosus with cyclosporin A. Arthritis Rheum. (1997) 40(1):27-35.
   PubMed Web of Science ®Google Scholar
• TOKUDA M, KURATA N, MIZOGUCHI A et al.: Effect of low-dose cyclosporin A on systemic lupus erythematosus disease activity. Arthritis Rheum. (1994) 37(4):551-558.
   PubMed Web of Science ®Google Scholar
• DUDDRIDGE M, POWELL RJ: Treatment of severe and difficult cases of systemic lupus erythematosus with tacrolimus. A report of three cases. Ann. Rheum. Dis. (1997) 56(11):690-692.
   PubMed Web of Science ®Google Scholar
• POLITT D, HEINTZ B, FLOEGE J, MERTENS PR: Tacrolimus- (FK 506) based immunosuppression in severe systemic lupus erythematosus. Clin. Nephrol. (2004) 62(1):49-53.
   PubMed Web of Science ®Google Scholar
• HOSHI K, MATSUDA M, ISHIKAWA M et al.: Successful treatment of fulminant pulmonary hemorrhage associated with systemic lupus erythematosus. Clin. Rheumatol. (2004) 23(3):252-255.
   PubMed Web of Science ®Google Scholar
• DONG G, PANARO F, BOGETTI D et al.: Standard chronic immunosuppression after kidney transplantation for systemic lupus erythematosus eliminates recurrence of disease. Clin. Transplant (2005) 19(1):56-60.
   PubMed Web of Science ®Google Scholar
• STONE JH, AMEND WJ, CRISWELL LA: Outcome of renal transplantation in ninety-seven cyclosporine-era patients with systemic lupus erythematosus and matched controls. Arthritis Rheum. (1998) 41(8):1438-1445.
   PubMed Web of Science ®Google Scholar
• KARIM MY, ALBA P, CUADRADO MJ et al.: Mycophenolate mofetil for systemic lupus erythematosus refractory to other immunosuppressive agents. Rheumatology (Oxford) (2002) 41(8):876-882.
   PubMed Web of Science ®Google Scholar
• CAMERON JS: Lupus nephritis. J. Am. Soc. Nephrol. (1999) 10(2):413-424.
   PubMed Web of Science ®Google Scholar
• MOK CC, WONG RW, LAI KN: Treatment of severe proliferative lupus nephritis: the current state. Ann. Rheum. Dis. (2003) 62(9):799-804.
   PubMed Web of Science ®Google Scholar
• BOUMPAS DT, AUSTIN HA III, VAUGHN EM et al.: Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet (1992) 340(8822):741-745.
   PubMed Web of Science ®Google Scholar
• CIRUELO E, DE LA CJ, LOPEZ I, GOMEZ-REINO JJ: Cumulative rate of relapse of lupus nephritis after successful treatment with cyclophosphamide. Arthritis Rheum. (1996) 39(12):2028-2034.
   PubMed Web of Science ®Google Scholar
• MORONI G, QUAGLINI S, MACCARIO M, BANFI G, PONTICELLI C: ‘Nephritic flares’ are predictors of bad long-term renal outcome in lupus nephritis. Kidney Int. (1996) 50(6):2047-2053.
   PubMed Web of Science ®Google Scholar
• IOANNIDIS JP, BOKI KA, KATSORIDA ME et al.: Remission, relapse, and re-remission of proliferative lupus nephritis treated with cyclophosphamide. Kidney Int. (2000) 57(1):258-264.
   PubMed Web of Science ®Google Scholar
• ILLEI GG, AUSTIN HA, CRANE M et al.: Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis. Ann. Intern. Med. (2001) 135(4):248-257.
   PubMed Web of Science ®Google Scholar
• BANSAL VK, BETO JA: Treatment of lupus nephritis: a meta-analysis of clinical trials. Am. J. Kidney Dis. (1997) 29(2):193-199.
   PubMed Web of Science ®Google Scholar
• FAVRE H, MIESCHER PA, HUANG YP, CHATELANAT F, MIHATSCH MJ: Ciclosporin in the treatment of lupus nephritis. Am. J. Nephrol. (1989) 9(Suppl. 1):57-60.
   PubMed Web of Science ®Google Scholar
• TAM LS, LI EK, LEUNG CB et al.: Long-term treatment of lupus nephritis with cyclosporin A. QJM (1998) 91(8):573-580.
   PubMed Web of Science ®Google Scholar
• FU LW, YANG LY, CHEN WP, LIN CY: Clinical efficacy of cyclosporin a neoral in the treatment of paediatric lupus nephritis with heavy proteinuria. Br. J. Rheumatol. (1998) 37(2):217-221.
   PubMedGoogle Scholar
• PISONI CN, KARIM Y, CUADRADO MJ: Mycophenolate mofetil and systemic lupus erythematosus: an overview. Lupus (2005) 14(Suppl. 1):s9-s11.
   PubMed Web of Science ®Google Scholar
• GINZLER EM, ARANOW C: Mycophenolate mofetil in lupus nephritis. Lupus (2005) 14(1):59-64.
   PubMed Web of Science ®Google Scholar
• MOK CC, HO CT, CHAN KW, LAU CS, WONG RW: Outcome and prognostic indicators of diffuse proliferative lupus glomerulonephritis treated with sequential oral cyclophosphamide and azathioprine. Arthritis Rheum. (2002) 46(4):1003-1013.
   PubMed Web of Science ®Google Scholar
• CONTRERAS G, PARDO V, LECLERCQ B et al.: Miantenance therapy for proliferative froms of lupus nephritis: a randomized controlled trial comparing quarterly intravenous cyclophosphamide versus oral mycophenolate mofetil or azathioprine. J. Am. Soc. Nephrol. (2002) 13:15A.
   Google Scholar
• CHAN TM, TSE KC, TANG CS, MOK MY, LI FK: Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis. J. Am. Soc. Nephrol. (2005) 16(4):1076-1084.
   PubMed Web of Science ®Google Scholar
• CONTRERAS G, ROTH D, PARDO V, STRIKER LG, SCHULTZ DR: Lupus nephritis: a clinical review for practicing nephrologists. Clin. Nephrol. (2002) 57(2):95-107.
   PubMed Web of Science ®Google Scholar
• CONTRERAS G, PARDO V, LECLERCQ B et al.: Sequential therapies for proliferative lupus nephritis. N. Engl. J. Med. (2004) 350(10):971-980.
   PubMed Web of Science ®Google Scholar
• CONTRERAS G, TOZMAN E, NAHAR N, METZ D: Maintenance therapies for proliferative lupus nephritis: mycophenolate mofetil, azathioprine and intravenous cyclophosphamide. Lupus (2005) 14(Suppl. 1):s33-s38.
   PubMed Web of Science ®Google Scholar
• DOOLEY MA, COSIO FG, NACHMAN PH et al.: Mycophenolate mofetil therapy in lupus nephritis: clinical observations. J. Am. Soc. Nephrol. (1999) 10(4):833-839.
   PubMed Web of Science ®Google Scholar
• BECKER CC, GIDAL BE, FLEMING JO: Immunotherapy in multiple sclerosis, part 1. Am. J. Health Syst. Pharm. (1995) 52(18):1985-2000.
   PubMed Web of Science ®Google Scholar
• CALLEGARO D, LANA-PEIXOTO MA, MOREIRA MA et al.: [The BCTRIMS Expanded Consensus on treatment of multiple sclerosis: I. The evidences for the use of immunosuppressive agents, plasma exchange and autologous hematopoietic stem cell transplantation]. Arq. Neuropsiquiatr. (2002) 60(3-B):869-874.
   PubMed Web of Science ®Google Scholar
• RIZVI SA, BASHIR K: Other therapy options and future strategies for treating patients with multiple sclerosis. Neurology (2004) 63(12 Suppl. 6):S47-S54.
   PubMed Web of Science ®Google Scholar
• RUDGE P: Cyclosporine and multiple sclerosis: the cons. Neurology (1988) 38(7 Suppl. 2):29-30.
   PubMed Web of Science ®Google Scholar
• KAPPOS L, PATZOLD U, DOMMASCH D et al.: Cyclosporine versus azathioprine in the long-term treatment of multiple sclerosis-results of the German multicenter study. Ann. Neurol. (1988) 23(1):56-63.
   PubMed Web of Science ®Google Scholar
• DOMMASCH D: Comparative clinical trial of cyclosporine in multiple sclerosis: the pros. Neurology (1988) 38(7 Suppl. 2):28-29.
   PubMedGoogle Scholar
• KERMAN RH, WOLINSKY JS, NATH A, SEARS ES Jr: Serial immune evaluation of cyclosporine- and placebo-treated multiple sclerosis patients. J. Neuroimmunol. (1988) 18(4):325-331.
   PubMed Web of Science ®Google Scholar
• Efficacy and toxicity of cyclosporine in chronic progressive multiple sclerosis: a randomized, double-blinded, placebo-controlled clinical trial. The Multiple Sclerosis Study Group. Ann. Neurol. (1990) 27(6):591-605.
   PubMed Web of Science ®Google Scholar
• SCHLUEP M, STECK AJ, DESPLAND PA et al.: [Efficacy and tolerance of cyclosporin A in the treatment of multiple sclerosis]. Schweiz. Rundsch. Med. Prax. (1991) 80(24):670-672.
   PubMedGoogle Scholar
• STECK AJ, REGLI F, OCHSNER F, GAUTHIER G: Cyclosporine versus azathioprine in the treatment of multiple sclerosis: 12-month clinical and immunological evaluation. Eur. Neurol. (1990) 30(4):224-228.
   PubMedGoogle Scholar
• HEFTI AF, ESHENAUR AE, HASSELL TM, STONE C: Gingival overgrowth in cyclosporine A treated multiple sclerosis patients. J. Periodontol. (1994) 65(8):744-749.
   PubMed Web of Science ®Google Scholar
• FUNAOKA M, KATO K, KOMATSU M et al.: Fulminant hepatitis caused by hepatitis C virus during treatment for multiple sclerosis. J. Gastroenterol. (1996) 31(1):119-122.
   PubMed Web of Science ®Google Scholar
• ZHAO GJ, LI DK, WOLINSKY JS et al.: Clinical and magnetic resonance imaging changes correlate in a clinical trial monitoring cyclosporine therapy for multiple sclerosis. The MS Study Group. J. Neuroimaging (1997) 7(1):1-7.
   PubMed Web of Science ®Google Scholar
• LEMSTER B, HUANG LL, IRISH W et al.: Influence of FK 506 (tacrolimus) on circulating CD4+ T cells expressing CD25 and CD45RA antigens in 19 patients with chronic progressive multiple sclerosis participating in an open label drug safety trial. Autoimmunity (1994) 19(2):89-98.
   PubMed Web of Science ®Google Scholar
• CARROLL PB, THOMSON AW, McCAULEY J et al.: Tacrolimus and therapy of human autoimmune disorders. In: Principles of Drug Development in Transplantation and Autoimmunity. Lieberman R, Mukherjee A (Eds), RG Landes Company and Chapman & Hall, Austin, USA (1996):211-220.
   Google Scholar
• McMICHAEL J, LIEBERMAN R, McCAULEY J, IRISH W, MARINO I, DOYLE H: Computer-guided randomized concentration-controlled trials of tacrolimus in autoimmunity: multiple sclerosis and primary biliary cirrhosis. Ther. Drug Monit. (1996) 18(4):435-437.
   PubMed Web of Science ®Google Scholar
• YOSHIDA EM, DEVONSHIRE VA, PROUT AJ: Remission of multiple sclerosis post-liver transplantation. Can. J. Neurol. Sci. (2004) 31(4):539-541.
   PubMed Web of Science ®Google Scholar
• CARLSON RP, HARTMAN DA, TOMCHEK LA et al.: Rapamycin, a potential disease-modifying antiarthritic drug. J. Pharmacol. Exp. Ther. (1993) 266(2):1125-1138.
   PubMed Web of Science ®Google Scholar
• VERMERSCH P, STOJKOVIC T, DE SEZE J: Mycophenolate mofetil and neurological diseases. Lupus (2005) 14(Suppl. 1):s42-s45.
   PubMed Web of Science ®Google Scholar
• FROHMAN EM, BRANNON K, RACKE MK, HAWKER K: Mycophenolate mofetil in multiple sclerosis. Clin. Neuropharmacol. (2004) 27(2):80-83.
   PubMed Web of Science ®Google Scholar
• AHMED S, KIRMANI JF, JANJUA N et al.: An update on myasthenic crisis. Curr. Treat. Options Neurol. (2005) 7(2):129-141.
   PubMedGoogle Scholar
• EVOLI A, BATOCCHI AP, TONALI P: A practical guide to the recognition and management of myasthenia gravis. Drugs (1996) 52(5):662-670.
   PubMed Web of Science ®Google Scholar
• RICHMAN DP, AGIUS MA: Treatment of autoimmune myasthenia gravis. Neurology (2003) 61(12):1652-1661.
   PubMed Web of Science ®Google Scholar
• SPRING PJ, SPIES JM: Myasthenia gravis: options and timing of immunomodulatory treatment. BioDrugs (2001) 15(3):173-183.
   PubMed Web of Science ®Google Scholar
• JUEL VC, MASSEY JM: Autoimmune myasthenia gravis: recommendations for treatment and immunologic modulation. Curr. Treat. Options Neurol. (2005) 7(1):3-14.
   PubMedGoogle Scholar
• TINDALL RS, ROLLINS JA, PHILLIPS JT, GREENLEE RG, WELLS L, BELENDIUK G: Preliminary results of a double-blind, randomized, placebo-controlled trial of cyclosporine in myasthenia gravis. N. Engl. J. Med. (1987) 316(12):719-724.
   PubMed Web of Science ®Google Scholar
• TINDALL RS, PHILLIPS JT, ROLLINS JA, WELLS L, HALL K: A clinical therapeutic trial of cyclosporine in myasthenia gravis. Ann. NY Acad. Sci. (1993) 681:539-551.
   PubMed Web of Science ®Google Scholar
• GOULON M, ELKHARRAT D, GAJDOS P: [Treatment of severe myasthenia gravis with cyclosporin. A 12-month open trial]. Presse. Med. (1989) 18(7):341-346.
   PubMed Web of Science ®Google Scholar
• BONIFATI DM, ANGELINI C: Long-term cyclosporine treatment in a group of severe myasthenia gravis patients. J. Neurol. (1997) 244(9):542-547.
   PubMed Web of Science ®Google Scholar
• CIAFALONI E, NIKHAR NK, MASSEY JM, SANDERS DB: Retrospective analysis of the use of cyclosporine in myasthenia gravis. Neurology (2000) 55(3):448-450.
   PubMed Web of Science ®Google Scholar
• LAVRNIC D, VUJIC A, RAKOCEVIC-STOJANOVIC V et al.: Cyclosporine in the treatment of myasthenia gravis. Acta Neurol. Scand. (2005) 111(4):247-252.
   PubMed Web of Science ®Google Scholar
• YOSHIKAWA H, IWASA K, SATOH K, TAKAMORI M: FK506 prevents induction of rat experimental autoimmune myasthenia gravis. J. Autoimmun. (1997) 10(1):11-16.
   PubMed Web of Science ®Google Scholar
• TSUKAGUCHI M, SHIMAMURA M, IKEDA K et al.: Low-dose tacrolimus for two cases of myasthenia gravis with invasive thymoma that relapsed shortly after thymectomy. J. Neurol. Sci. (2005) 231(1-2):85-88.
   PubMed Web of Science ®Google Scholar
• KONISHI T, SANADA M, TAKEHANA K: Myasthenic crisis after the cessation of FK506 in a patient with myasthenia gravis. J. Neurol. (2004) 251(9):1154-1155.
   PubMed Web of Science ®Google Scholar
• RODRIGUEZ D, CID-RODRIGUEZ MC, NUNEZ-ALVAREZ ML, GONZALEZ-VAZQUEZ E, LUSTRES-PEREZ M: [Meningitis caused by Listeria monocytogenes in a patient with myasthenia gravis being treated with tacrolimus]. Rev. Neurol. (2005) 40(6):383.
   PubMed Web of Science ®Google Scholar
• PONSETI JM, AZEM J, FORT JM, CODINA A, MONTORO JB, ARMENGOL M: Benefits of FK506 (tacrolimus) for residual, cyclosporin- and prednisone-resistant myasthenia gravis: one-year follow-up of an open-label study. Clin. Neurol. Neurosurg. (2005) 107(3):187-190.
   PubMed Web of Science ®Google Scholar
• KONISHI T, YOSHIYAMA Y, TAKAMORI M, YAGI K, MUKAI E, SAIDA T: Clinical study of FK506 in patients with myasthenia gravis. Muscle Nerve (2003) 28(5):570-574.
   PubMed Web of Science ®Google Scholar
• WAKATA N, SAITO T, TANAKA S, HIRANO T, OKA K: Tacrolimus hydrate (FK506): therapeutic effects and selection of responders in the treatment of myasthenia gravis. Clin. Neurol. Neurosurg. (2003) 106(1):5-8.
   PubMed Web of Science ®Google Scholar
• KAWAGUCHI N, YOSHIYAMA Y, NEMOTO Y, MUNAKATA S, FUKUTAKE T, HATTORI T: Low-dose tacrolimus treatment in thymectomised and steroid-dependent myasthenia gravis. Curr. Med. Res. Opin. (2004) 20(8):1269-1273.
   PubMed Web of Science ®Google Scholar
• KONISHI T, YOSHIYAMA Y, TAKAMORI M, SAIDA T: Long-term treatment of generalised myasthenia gravis with FK506 (tacrolimus). J. Neurol. Neurosurg. Psychiatry (2005) 76(3):448-450.
   PubMed Web of Science ®Google Scholar
• HAUSER RA, MALEK AR, ROSEN R: Successful treatment of a patient with severe refractory myasthenia gravis using mycophenolate mofetil. Neurology (1998) 51(3):912-913.
   PubMedGoogle Scholar
• MOWZOON N, SUSSMAN A, BRADLEY WG: Mycophenolate (CellCept) treatment of myasthenia gravis, chronic inflammatory polyneuropathy and inclusion body myositis. J. Neurol. Sci. (2001) 185(2):119-122.
   PubMed Web of Science ®Google Scholar
• CHAUDHRY V, CORNBLATH DR, GRIFFIN JW, O’BRIEN R, DRACHMAN DB: Mycophenolate mofetil: a safe and promising immunosuppressant in neuromuscular diseases. Neurology (2001) 56(1):94-96.
   PubMed Web of Science ®Google Scholar
• SCHNEIDER C, GOLD R, REINERS K, TOYKA KV: Mycophenolate mofetil in the therapy of severe myasthenia gravis. Eur. Neurol. (2001) 46(2):79-82.
   PubMed Web of Science ®Google Scholar
• CIAFALONI E, MASSEY JM, TUCKER-LIPSCOMB B, SANDERS DB: Mycophenolate mofetil for myasthenia gravis: an open-label pilot study. Neurology (2001) 56(1):97-99.
   PubMed Web of Science ®Google Scholar
• MERIGGIOLI MN, CIAFALONI E, AL HAYK KA et al.: Mycophenolate mofetil for myasthenia gravis: an analysis of efficacy, safety, and tolerability. Neurology (2003) 61(10):1438-1440.
   PubMed Web of Science ®Google Scholar
• MERIGGIOLI MN, ROWIN J: Single fiber EMG as an outcome measure in myasthenia gravis: results from a double-blind, placebo-controlled trial. J. Clin. Neurophysiol. (2003) 20(5):382-385.
   PubMed Web of Science ®Google Scholar
• CIAFALONI E: Mycophenolate mofetil and myasthenia gravis. Lupus (2005) 14(Suppl. 1):s46-s49.
   PubMed Web of Science ®Google Scholar
• SCHRADER P, MOOSER G, PETER RU, PUHL W: [Preliminary results in the therapy of psoriatic arthritis with mycophenolate mofetil]. Z. Rheumatol. (2002) 61(5):545-550.
   PubMed Web of Science ®Google Scholar
• JONES G, CROTTY M, BROOKS P: Interventions for psoriatic arthritis. Cochrane Database Syst. Rev. (2000) 3:CD000212.
   PubMedGoogle Scholar
• SALVARANI C, MACCHIONI P, OLIVIERI I et al.: A comparison of cyclosporine, sulfasalazine, and symptomatic therapy in the treatment of psoriatic arthritis. J. Rheumatol. (2001) 28(10):2274-2282.
   PubMed Web of Science ®Google Scholar
• KALTWASSER JP, NASH P, GLADMAN D et al.: Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: a multinational, double-blind, randomized, placebo-controlled clinical trial. Arthritis Rheum. (2004) 50(6):1939-1950.
   PubMed Web of Science ®Google Scholar
• GRUNDMANN-KOLLMANN M, MOOSER G, SCHRAEDER P et al.: Treatment of chronic plaque-stage psoriasis and psoriatic arthritis with mycophenolate mofetil. J. Am. Acad. Dermatol. (2000) 42(5 Part 1):835-837.
   PubMed Web of Science ®Google Scholar
• GISONDI P, GUBINELLI E, COCUROCCIA B, GIROLOMONI G: Targeting tumor necrosis factor-alpha in the therapy of psoriasis. Curr. Drug Targets Inflamm. Allergy (2004) 3(2):175-183.
   PubMedGoogle Scholar
• ANTONI CE, KAVANAUGH A, KIRKHAM B et al.: Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis Rheum. (2005) 52(4):1227-1236.
   PubMed Web of Science ®Google Scholar
• MEASE PJ, GOFFE BS, METZ J, VANDERSTOEP A, FINCK B, BURGE DJ: Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet (2000) 356(9227):385-390.
   PubMed Web of Science ®Google Scholar
• MEASE PJ: Etanercept, a TNF antagonist for treatment for psoriatic arthritis and psoriasis. Skin Therapy Lett. (2003) 8(1):1-4.
   PubMedGoogle Scholar
• HELMS C, CAO L, KRUEGER JG et al.: A putative RUNX1 binding site variant between SLC9A3R1 and NAT9 is associated with susceptibility to psoriasis. Nat. Genet. (2003) 35(4):349-356.
   PubMed Web of Science ®Google Scholar
• SAINI R, TUTRONE WD, WEINBERG JM: Advances in therapy for psoriasis: an overview of infliximab, etanercept, efalizumab, alefacept, adalimumab, tazarotene, and pimecrolimus. Curr. Pharm. Des. (2005) 11(2):273-280.
   PubMed Web of Science ®Google Scholar
• LEBWOHL M, ALI S: Treatment of psoriasis. Part 2. Systemic therapies. J. Am. Acad. Dermatol. (2001) 45(5):649-661.
   PubMed Web of Science ®Google Scholar
• ELLIS CN, GORSULOWSKY DC, HAMILTON TA et al.: Cyclosporine improves psoriasis in a double-blind study. J. Am. Med. Assoc. (1986) 256(22):3110-3116.
   PubMed Web of Science ®Google Scholar
• Short- and long-term considerations concerning the management of plaque psoriasis with low-dose cyclosporin. Studio Italiano Multicentrico nella Psoriasi (SIMPSO). Dermatology (1993) 187(Suppl. 1):19-29.
   Google Scholar
• HONEYMAN JF, SANCHEZ L, VALDES P: Low-dose cyclosporine A improves severe disabling psoriasis in Latin America. Latin American Multicenter Study. Int. J. Dermatol. (1995) 34(8):583-588.
   PubMed Web of Science ®Google Scholar
• SHUPACK J, ABEL E, BAUER E et al.: Cyclosporine as maintenance therapy in patients with severe psoriasis. J. Am. Acad. Dermatol. (1997) 36(3 Part 1):423-432.
   PubMed Web of Science ®Google Scholar
• HO VC, GRIFFITHS CE, ALBRECHT G et al.: Intermittent short courses of cyclosporin (Neoral®) for psoriasis unresponsive to topical therapy: a 1-year multicentre, randomized study. The PISCES Study Group. Br. J. Dermatol. (1999) 141(2):283-291.
   PubMed Web of Science ®Google Scholar
• OZAWA A, SUGAI J, OHKIDO M et al.: Cyclosporin in psoriasis: continuous monotherapy versus intermittent long-term therapy. Eur. J. Dermatol. (1999) 9(3):218-223.
   PubMed Web of Science ®Google Scholar
• TOUW CR, HAKKAART-VAN ROIJEN L, VERBOOM P, PAUL C, RUTTEN FF, FINLAY AY: Quality of life and clinical outcome in psoriasis patients using intermittent cyclosporin. Br. J. Dermatol. (2001) 144(5):967-972.
   PubMed Web of Science ®Google Scholar
• OHTSUKI M, NAKAGAWA H, SUGAI J et al.: Long-term continuous versus intermittent cyclosporin: therapy for psoriasis. J. Dermatol. (2003) 30(4):290-298.
   PubMed Web of Science ®Google Scholar
• SALEK MS, FINLAY AY, LEWIS JJ, SUMNER MI: Quality of life improvement in treatment of psoriasis with intermittent short course cyclosporin (Neoral). Qual. Life Res. (2004) 13(1):91-95.
   PubMed Web of Science ®Google Scholar
• LABURTE C, GROSSMAN R, ABI-RACHED J, ABEYWICKRAMA KH, DUBERTRET L: Efficacy and safety of oral cyclosporin A (CyA; Sandimmun) for long-term treatment of chronic severe plaque psoriasis. Br. J. Dermatol. (1994) 130(3):366-375.
   PubMed Web of Science ®Google Scholar
• JAN V, VAILLANT L, BRESSIEUX JM et al.: Short-term cyclosporin monotherapy for chronic severe plaque-type psoriasis. Eur. J. Dermatol. (1999) 9(8):615-617.
   PubMed Web of Science ®Google Scholar
• THACI D, BRAUTIGAM M, KAUFMANN R, WEIDINGER G, PAUL C, CHRISTOPHERS E: Body-weight-independent dosing of cyclosporine micro-emulsion and three times weekly maintenance regimen in severe psoriasis. A randomised study. Dermatology (2002) 205(4):383-388.
   PubMed Web of Science ®Google Scholar
• SPADARO A, RICCIERI V, SILI-SCAVALLI A, SENSI F, TACCARI E, ZOPPINI A: Comparison of cyclosporin A and methotrexate in the treatment of psoriatic arthritis: a one-year prospective study. Clin. Exp. Rheumatol. (1995) 13(5):589-593.
   PubMed Web of Science ®Google Scholar
• HEYDENDAEL VM, SPULS PI, OPMEER BC et al.: Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis. N. Engl. J. Med. (2003) 349(7):658-665.
   PubMed Web of Science ®Google Scholar
• SANDHU K, KAUR I, KUMAR B, SARASWAT A: Efficacy and safety of cyclosporine versus methotrexate in severe psoriasis: a study from north India. J. Dermatol. (2003) 30(6):458-463.
   PubMed Web of Science ®Google Scholar
• HO VC, GRIFFITHS CE, BERTH-JONES J et al.: Intermittent short courses of cyclosporine microemulsion for the long-term management of psoriasis: a 2-year cohort study. J. Am. Acad. Dermatol. (2001) 44(4):643-651.
   PubMed Web of Science ®Google Scholar
• MROWIETZ U, FARBER L, HENNEICKE-VON ZEPELIN HH, BACHMANN H, WELZEL D, CHRISTOPHERS E: Long-term maintenance therapy with cyclosporine and posttreatment survey in severe psoriasis: results of a multicenter study. German Multicenter Study. J. Am. Acad. Dermatol. (1995) 33(3):470-475.
   PubMed Web of Science ®Google Scholar
• ELLIS CN, FRADIN MS, HAMILTON TA, VOORHEES JJ: Duration of remission during maintenance cyclosporine therapy for psoriasis. Relationship to maintenance dose and degree of improvement during initial therapy. Arch. Dermatol. (1995) 131(7):791-795.
   PubMed Web of Science ®Google Scholar
• FAERBER L, BRAEUTIGAM M, WEIDINGER G et al.: Cyclosporine in severe psoriasis. Results of a meta-analysis in 579 patients. Am. J. Clin. Dermatol. (2001) 2(1):41-47.
   PubMedGoogle Scholar
• ELDER CA, MOORE M, CHANG CT et al.: Efficacy and pharmacokinetics of two formulations of cyclosporine A in patients with psoriasis. J. Clin. Pharmacol. (1995) 35(9):865-875.
   PubMed Web of Science ®Google Scholar
• ERKKO P, GRANLUND H, NUUTINEN M, REITAMO S: Comparison of cyclosporin A pharmacokinetics of a new microemulsion formulation and standard oral preparation in patients with psoriasis. Br. J. Dermatol. (1997) 136(1):82-88.
   PubMed Web of Science ®Google Scholar
• KOO J: A randomized, double-blind study comparing the efficacy, safety and optimal dose of two formulations of cyclosporin, Neoral and Sandimmun, in patients with severe psoriasis. OLP302 Study Group. Br. J. Dermatol. (1998) 139(1):88-95.
   PubMed Web of Science ®Google Scholar
• LEBWOHL M, ELLIS C, GOTTLIEB A et al.: Cyclosporine consensus conference: with emphasis on the treatment of psoriasis. J. Am. Acad. Dermatol. (1998) 39(3):464-475.
   PubMed Web of Science ®Google Scholar
• ZACHARIAE H, ABRAMS B, BLEEHEN SS et al.: Conversion of psoriasis patients from the conventional formulation of cyclosporin A to a new microemulsion formulation: a randomized, open, multicentre assessment of safety and tolerability. Dermatology (1998) 196(2):231-236.
   PubMed Web of Science ®Google Scholar
• POWLES AV, HARDMAN CM, PORTER WM, COOK T, HULME B, FRY L: Renal function after 10 years’ treatment with cyclosporin for psoriasis. Br. J. Dermatol. (1998) 138(3):443-449.
   PubMed Web of Science ®Google Scholar
• SARZI-PUTTINI P, CAZZOLA M, PANNI B et al.: Long-term safety and efficacy of low-dose cyclosporin A in severe psoriatic arthritis. Rheumatol. Int. (2002) 21(6):234-238.
   PubMed Web of Science ®Google Scholar
• MARKHAM T, WATSON A, ROGERS S: Adverse effects with long-term cyclosporin for severe psoriasis. Clin. Exp. Dermatol. (2002) 27(2):111-114.
   PubMed Web of Science ®Google Scholar
• GARCIA-BUSTINDUY M, ESCODA M, GUIMERA FJ et al.: Safety of long-term treatment with cyclosporin A in resistant chronic plaque psoriasis: a retrospective case series. J. Eur. Acad. Dermatol. Venereol. (2004) 18(2):169-172.
   PubMed Web of Science ®Google Scholar
• ZACHARIAE H, KRAGBALLE K, HANSEN HE, MARCUSSEN N, OLSEN S: [Renal biopsy in connection with long-term treatment of psoriasis with cyclosporine]. Ugeskr. Laeger. (1998) 160(31):4534-4538.
   PubMedGoogle Scholar
• HEYDENDAEL VM, SPULS PI, TEN BERGE IJ, OPMEER BC, BOS JD, DE RIE MA: Cyclosporin trough levels: is monitoring necessary during short-term treatment in psoriasis? A systematic review and clinical data on trough levels. Br. J. Dermatol. (2002) 147(1):122-129.
   PubMed Web of Science ®Google Scholar
• LAIN EL, MARKUS RF: Early and explosive development of nodular basal cell carcinoma and multiple keratoacanthomas in psoriasis patients treated with cyclosporine. J. Drugs Dermatol. (2004) 3(6):680-682.
   PubMedGoogle Scholar
• BEHNAM SM, BEHNAM SE, KOO JY: Review of cyclosporine immunosuppressive safety data in dermatology patients after two decades of use. J. Drugs Dermatol. (2005) 4(2):189-194.
   PubMedGoogle Scholar
• LELIEVRE JD, SACRE K, ADLE-BIASSETTE H, MOLINIER-FRENKEL V, GAULARD P, PAPO T: Epstein-Barr virus-associated lymphoproliferative disease after long-standing cyclosporine therapy for psoriasis: a case of spontaneous regression. J. Am. Acad. Dermatol. (2005) 52(2 Suppl. 1):24-27.
   PubMed Web of Science ®Google Scholar
• PAUL CF, HO VC, McGEOWN C et al.: Risk of malignancies in psoriasis patients treated with cyclosporine: a 5 y cohort study. J. Invest. Dermatol. (2003) 120(2):211-216.
   PubMed Web of Science ®Google Scholar
• HO VC: The use of ciclosporin in psoriasis: a clinical review. Br. J. Dermatol. (2004) 150(Suppl. 67):1-10.
   PubMedGoogle Scholar
• PEARCE DJ, THOMAS CG, FLEISCHER AB Jr, FELDMAN SR: The cost of psoriasis therapies: considerations for therapy selection. Dermatol. Nurs. (2004) 16(5):421-428.
   PubMedGoogle Scholar
• OPMEER BC, HEYDENDAEL VM, DE BORGIE CA et al.: Costs of treatment in patients with moderate to severe plaque psoriasis: economic analysis in a randomized controlled comparison of methotrexate and cyclosporine. Arch. Dermatol. (2004) 140(6):685-690.
   PubMed Web of Science ®Google Scholar
• GRIFFITHS CE, DUBERTRET L, ELLIS CN et al.: Ciclosporin in psoriasis clinical practice: an international consensus statement. Br. J. Dermatol. (2004) 150(Suppl. 67):11-23.
   PubMed Web of Science ®Google Scholar
• JEGASOTHY BV, ACKERMAN CD, TODO S, FUNG JJ, ABU-ELMAGD K, STARZL TE: Tacrolimus (FK 506)-a new therapeutic agent for severe recalcitrant psoriasis. Arch. Dermatol. (1992) 128(6):781-785.
   PubMed Web of Science ®Google Scholar
• THOMSON AW, NALESNIK MA, RILO HR, WOO J, CARROLL PB, VAN THIEL DH: ICAM-1 and E-selectin expression in lesional biopsies of psoriasis patients responding to systemic FK 506 therapy. Autoimmunity (1993) 15(3):215-223.
   PubMed Web of Science ®Google Scholar
• SKAEHILL PA: Tacrolimus in dermatologic disorders. Ann. Pharmacother. (2001) 35(5):582-588.
   PubMed Web of Science ®Google Scholar
• MARSLAND AM, GRIFFITHS CE: The macrolide immunosuppressants in dermatology: mechanisms of action. Eur. J. Dermatol. (2002) 12(6):618-622.
   PubMed Web of Science ®Google Scholar
• STANDER S, LUGER TA: [Antipruritic effects of pimecrolimus and tacrolimus]. Hautarzt (2003) 54(5):413-417.
   PubMed Web of Science ®Google Scholar
• LEBWOHL M, FREEMAN AK, CHAPMAN MS, FELDMAN SR, HARTLE JE, HENNING A: Tacrolimus ointment is effective for facial and intertriginous psoriasis. J. Am. Acad. Dermatol. (2004) 51(5):723-730.
   PubMed Web of Science ®Google Scholar
• YAMAMOTO T, NISHIOKA K: Topical tacrolimus: an effective therapy for facial psoriasis. Eur. J. Dermatol. (2003) 13(5):471-473.
   PubMed Web of Science ®Google Scholar
• FREEMAN AK, LINOWSKI GJ, BRADY C et al.: Tacrolimus ointment for the treatment of psoriasis on the face and intertriginous areas. J. Am. Acad. Dermatol. (2003) 48(4):564-568.
   PubMed Web of Science ®Google Scholar
• ZONNEVELD IM, RUBINS A, JABLONSKA S et al.: Topical tacrolimus is not effective in chronic plaque psoriasis. A pilot study. Arch. Dermatol. (1998) 134(9):1101-1102.
   PubMed Web of Science ®Google Scholar
• CARROLL CL, CLARKE J, CAMACHO F, BALKRISHNAN R, FELDMAN SR: Topical tacrolimus ointment combined with 6% salicylic acid gel for plaque psoriasis treatment. Arch. Dermatol. (2005) 141(1):43-46.
   PubMed Web of Science ®Google Scholar
• REITAMO S, SPULS P, SASSOLAS B, LAHFA M, CLAUDY A, GRIFFITHS CE: Efficacy of sirolimus (rapamycin) administered concomitantly with a subtherapeutic dose of cyclosporin in the treatment of severe psoriasis: a randomized controlled trial. Br. J. Dermatol. (2001) 145(3):438-445.
   PubMed Web of Science ®Google Scholar
• KAPLAN MJ, ELLIS CN, BATA-CSORGO Z, KAPLAN RS, ENDRES JL, FOX DA: Systemic toxicity following administration of sirolimus (formerly rapamycin) for psoriasis: association of capillary leak syndrome with apoptosis of lesional lymphocytes. Arch. Dermatol. (1999) 135(5):553-557.
   PubMed Web of Science ®Google Scholar
• ORMEROD AD, SHAH SA, COPELAND P, OMAR G, WINFIELD A: Treatment of psoriasis with topical sirolimus: preclinical development and a randomized, double-blind trial. Br. J. Dermatol. (2005) 152(4):758-764.
   PubMed Web of Science ®Google Scholar
• NOUSARI HC, SRAGOVICH A, KIMYAI-ASADI A, ORLINSKY D, ANHALT GJ: Mycophenolate mofetil in autoimmune and inflammatory skin disorders. J. Am. Acad. Dermatol. (1999) 40(2 Part 1):265-268.
   PubMed Web of Science ®Google Scholar
• TONG DW, WALDER BK: Widespread plaque psoriasis responsive to mycophenolate mofetil. Australas J. Dermatol. (1999) 40(3):135-137.
   PubMed Web of Science ®Google Scholar
• DAVISON SC, MORRIS-JONES R, POWLES AV, FRY L: Change of treatment from cyclosporin to mycophenolate mofetil in severe psoriasis. Br. J. Dermatol. (2000) 143(2):405-407.
   PubMed Web of Science ®Google Scholar
• AMEEN M, SMITH HR, BARKER JN: Combined mycophenolate mofetil and cyclosporin therapy for severe recalcitrant psoriasis. Clin. Exp. Dermatol. (2001) 26(6):480-483.
   PubMed Web of Science ®Google Scholar
• ZHOU Y, ROSENTHAL D, DUTZ J, HO V: Mycophenolate mofetil (CellCept®) for psoriasis: a two-center, prospective, open-label clinical trial. J. Cutan. Med. Surg. (2003) 7(3):193-197.
   PubMed Web of Science ®Google Scholar
• DAUDEN E, SANCHEZ-PEINADO C, RUIZ-GENAO D, GARCIA F V, ONATE MJ, GARCIA-DIEZ A: Plasma trough levels of mycophenolic acid do not correlate with efficacy and safety of mycophenolate mofetil in psoriasis. Br. J. Dermatol. (2004) 150(1):132-135.
   PubMed Web of Science ®Google Scholar
• JAHN K, FISCHER A, NEUBERT RH, WOHLRAB J: Investigation of the penetration behaviour of mycophenolate mofetil from a semisolid formulation into human skin ex vivo. J. Pharm. Pharmacol. (2001) 53(12):1581-1587.
   PubMed Web of Science ®Google Scholar
• HARTMANN M, ENK A: Mycophenolate mofetil and skin diseases. Lupus (2005) 14(Suppl. 1):s58-s63.
   PubMed Web of Science ®Google Scholar
• DROSOS AA: Newer immunosuppressive drugs: their potential role in rheumatoid arthritis therapy. Drugs (2002) 62(6):891-907.
   PubMed Web of Science ®Google Scholar
• CASE JP: Old and new drugs used in rheumatoid arthritis: a historical perspective. Part 1: the older drugs. Am. J. Ther. (2001) 8(2):123-143.
   PubMedGoogle Scholar
• GOTZSCHE PC, JOHANSEN HK: Short-term low-dose corticosteroids versus placebo and nonsteroidal antiinflammatory drugs in rheumatoid arthritis. Cochrane Database Syst. Rev. (2004) 3:CD000189.
   PubMedGoogle Scholar
• NURMOHAMED MT, DIJKMANS BA: Efficacy, tolerability and cost effectiveness of disease-modifying antirheumatic drugs and biologic agents in rheumatoid arthritis. Drugs (2005) 65(5):661-694.
   PubMed Web of Science ®Google Scholar
• YAZICI Y, SOKKA T, KAUTIAINEN H, SWEARINGEN C, KULMAN I, PINCUS T: Long term safety of methotrexate in routine clinical care: discontinuation is unusual and rarely the result of laboratory abnormalities. Ann. Rheum. Dis. (2005) 64(2):207-211.
   PubMed Web of Science ®Google Scholar
• KREMER JM: Rational use of new and existing disease-modifying agents in rheumatoid arthritis. Ann. Intern. Med. (2001) 134(8):695-706.
   PubMed Web of Science ®Google Scholar
• Cutaneous ulceration with methotrexate. Prescrire Int. (2003) 12(64):59-60.
   PubMedGoogle Scholar
• OSIRI M, SHEA B, ROBINSON V et al.: Leflunomide for the treatment of rheumatoid arthritis: a systematic review and metaanalysis. J. Rheumatol. (2003) 30(6):1182-1190.
   PubMed Web of Science ®Google Scholar
• MADDISON P, KIELY P, KIRKHAM B et al.: Leflunomide in rheumatoid arthritis: recommendations through a process of consensus. Rheumatology (Oxford) (2005) 44(3):280-286.
   PubMed Web of Science ®Google Scholar
• MADHOK R, TORLEY HI, CAPELL HA: A study of the longterm efficacy and toxicity of cyclosporine A in rheumatoid arthritis. J. Rheumatol. (1991) 18(10):1485-1489.
   PubMed Web of Science ®Google Scholar
• KRUGER K, SCHATTENKIRCHNER M: Comparison of cyclosporin A and azathioprine in the treatment of rheumatoid arthritis-results of a double-blind multicentre study. Clin. Rheumatol. (1994) 13(2):248-255.
   PubMed Web of Science ®Google Scholar
• TUGWELL P, PINCUS T, YOCUM D et al.: Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis. The Methotrexate–Cyclosporine Combination Study Group. N. Engl. J. Med. (1995) 333(3):137-141.
   PubMed Web of Science ®Google Scholar
• YOCUM DE: Combination therapy with cyclosporin in rheumatoid arthritis. Br. J. Rheumatol. (1996) 35(Suppl. 2):19-23.
   PubMedGoogle Scholar
• GREMESE E, FERRACCIOLI GF: Benefit/risk of cyclosporine in rheumatoid arthritis. Clin. Exp. Rheumatol. (2004) 22(5 Suppl. 35):S101-S107.
   PubMed Web of Science ®Google Scholar
• FAROOQUI AN, AHMAD SL, MANSURI FA: Efficacy of cyclosporin-A in refractory rheumatoid arthritis. J. Coll. Physicians Surg. Pak. (2004) 14(3):139-141.
   PubMedGoogle Scholar
• FOX RI, MORGAN SL, SMITH HT, ROBBINS BA, CHOC MG, BAGGOTT JE: Combined oral cyclosporin and methotrexate therapy in patients with rheumatoid arthritis elevates methotrexate levels and reduces 7-hydroxymethotrexate levels when compared with methotrexate alone. Rheumatology (Oxford) (2003) 42(8):989-994.
   PubMed Web of Science ®Google Scholar
• RODRIGUEZ F, KRAYENBUHL JC, HARRISON WB et al.: Renal biopsy findings and followup of renal function in rheumatoid arthritis patients treated with cyclosporin A. An update from the International Kidney Biopsy Registry. Arthritis Rheum. (1996) 39(9):1491-1498.
   PubMedGoogle Scholar
• KOVARIK JM, KURKI P, MUELLER E et al.: Diclofenac combined with cyclosporine in treatment refractory rheumatoid arthritis: longitudinal safety assessment and evidence of a pharmacokinetic/dynamic interaction. J. Rheumatol. (1996) 23(12):2033-2038.
   PubMed Web of Science ®Google Scholar
• YOCUM DE, ALLARD S, COHEN SB et al.: Microemulsion formulation of cyclosporin (Sandimmun Neoral) versus Sandimmun: comparative safety, tolerability and efficacy in severe active rheumatoid arthritis. On behalf of the OLR 302 Study Group. Rheumatology (Oxford) (2000) 39(2):156-164.
   PubMed Web of Science ®Google Scholar
• ALTMAN RD, SCHIFF M, KOPP EJ: Cyclosporine A in rheumatoid arthritis: randomized, placebo controlled dose finding study. J. Rheumatol. (1999) 26(10):2102-2109.
   PubMed Web of Science ®Google Scholar
• JOHNS KR, LITTLEJOHN GO: The safety and efficacy of cyclosporine (Neoral) in rheumatoid arthritis. J. Rheumatol. (1999) 26(10):2110-2113.
   PubMed Web of Science ®Google Scholar
• MARCHESONI A, BATTAFARANO N, ARREGHINI M et al.: Step-down approach using either cyclosporin A or methotrexate as maintenance therapy in early rheumatoid arthritis. Arthritis Rheum. (2002) 47(1):59-66.
   PubMed Web of Science ®Google Scholar
• GERARDS AH, LANDEWE RB, PRINS AP et al.: Cyclosporin A monotherapy versus cyclosporin A and methotrexate combination therapy in patients with early rheumatoid arthritis: a double blind randomised placebo controlled trial. Ann. Rheum. Dis. (2003) 62(4):291-296.
   PubMed Web of Science ®Google Scholar
• MIRANDA JM, ALVAREZ-NEMEGYEI J, SAAVEDRA MA et al.: A randomized, double-blind, multicenter, controlled clinical trial of cyclosporine plus chloroquine versus cyclosporine plus placebo in early-onset rheumatoid arthritis. Arch. Med. Res. (2004) 35(1):36-42.
   PubMed Web of Science ®Google Scholar
• ZEIDLER HK, KVIEN TK, HANNONEN P et al.: Progression of joint damage in early active severe rheumatoid arthritis during 18 months of treatment: comparison of low-dose cyclosporin and parenteral gold. Br. J. Rheumatol. (1998) 37(8):874-882.
   PubMedGoogle Scholar
• KVIEN TK, ZEIDLER HK, HANNONEN P et al.: Long term efficacy and safety of cyclosporin versus parenteral gold in early rheumatoid arthritis: a three year study of radiographic progression, renal function, and arterial hypertension. Ann. Rheum. Dis. (2002) 61(6):511-516.
   PubMed Web of Science ®Google Scholar
• TEMEKONIDIS TI, GEORGIADIS AN, ALAMANOS Y, BOUGIAS DV, VOULGARI PV, DROSOS AA: Infliximab treatment in combination with cyclosporin A in patients with severe refractory rheumatoid arthritis. Ann. Rheum. Dis. (2002) 61(9):822-825.
   PubMed Web of Science ®Google Scholar
• DUMONT FJ: ISAtx-247 (Isotechnika/Roche). Curr. Opin. Investig. Drugs (2004) 5(5):542-550.
   PubMedGoogle Scholar
• GREMILLION RB, POSEVER JO, MANEK N, WEST JP, VOLEN-HOVEN RF: Tacrolimus (FK506) in the treatment of severe, refractory rheumatoid arthritis: initial experience in 12 patients. J. Rheumatol. (1999) 26(11):2332-2336.
   PubMed Web of Science ®Google Scholar
• FURST DE, SAAG K, FLEISCHMANN MR et al.: Efficacy of tacrolimus in rheumatoid arthritis patients who have been treated unsuccessfully with methotrexate: a six-month, double-blind, randomized, dose-ranging study. Arthritis Rheum. (2002) 46(8):2020-2028.
   PubMed Web of Science ®Google Scholar
• YOCUM DE, FURST DE, KAINE JL et al.: Efficacy and safety of tacrolimus in patients with rheumatoid arthritis: a double-blind trial. Arthritis Rheum. (2003) 48(12):3328-3337.
   PubMed Web of Science ®Google Scholar
• KONDO H, ABE T, HASHIMOTO H et al.: Efficacy and safety of tacrolimus (FK506) in treatment of rheumatoid arthritis: a randomized, double blind, placebo controlled dose-finding study. J. Rheumatol. (2004) 31(2):243-251.
   PubMed Web of Science ®Google Scholar
• KREMER JM, HABROS JS, KOLBA KS et al.: Tacrolimus in rheumatoid arthritis patients receiving concomitant methotrexate: a six-month, open-label study. Arthritis Rheum. (2003) 48(10):2763-2768.
   PubMed Web of Science ®Google Scholar
• PARKER CT, RENNIE T: Failure to report previously used drugs and dosages in pharmaceutical company-sponsored rheumatoid arthritis trials: comment on the article by Yocum et al.: Arthritis Rheum. (2004) 50(9):3051-3052.
   PubMed Web of Science ®Google Scholar
• YOCUM DE, FURST DE, BENSEN WG et al.: Safety of tacrolimus in patients with rheumatoid arthritis: long-term experience. Rheumatology (Oxford) (2004) 43(8):992-999.
   PubMed Web of Science ®Google Scholar
• MIGITA K, EGUCHI K, AOYAGI T et al.: The effects of the immunosuppressant rapamycin on the growth of rheumatoid arthritis (RA) synovial fibroblast. Clin. Exp. Immunol. (1996) 104(1):86-91.
   PubMed Web of Science ®Google Scholar
• FORONCEWICZ B, MUCHA K, PACZEK L, CHMURA A, ROWINSKI W: Efficacy of rapamycin in patient with juvenile rheumatoid arthritis. Transpl. Int. (2005) 18(3):366-368.
   PubMed Web of Science ®Google Scholar
• Temsirolimus: CCI 779, CCI-779, cell cycle inhibitor-779. Drugs R D (2004) 5(6):363-367.
   PubMedGoogle Scholar
• GOLDBLUM R: Therapy of rheumatoid arthritis with mycophenolate mofetil. Clin. Exp. Rheumatol. (1993) 11(Suppl. 8):S117-S119.
   PubMed Web of Science ®Google Scholar
• PORTINCASA P, VACCA M, MOSCHETTA A et al.: Primary sclerosing cholangitis: updates in diagnosis and therapy. World J. Gastroenterol. (2005) 11(1):16.
   Google Scholar
• KUGELMAS M, SPIEGELMAN P, OSGOOD MJ et al.: Different immunosuppressive regimens and recurrence of primary sclerosing cholangitis after liver transplantation. Liver Transpl. (2003) 9(7):727-732.
   PubMed Web of Science ®Google Scholar
• BURAK K, ANGULO P, PASHA TM, EGAN K, PETZ J, LINDOR KD: Incidence and risk factors for cholangiocarcinoma in primary sclerosing cholangitis. Am. J. Gastroenterol. (2004) 99(3):523-526.
   PubMed Web of Science ®Google Scholar
• HAAGSMA EB, VAN DEN BERG AP, KLEIBEUKER JH, SLOOFF MJ, DIJKSTRA G: Inflammatory bowel disease after liver transplantation: the effect of different immunosuppressive regimens. Aliment. Pharmacol. Ther. (2003) 18(1):33-44.
   PubMed Web of Science ®Google Scholar
• BOBERG KM, EGELAND T, SCHRUMPF E: Long-term effect of corticosteroid treatment in primary sclerosing cholangitis patients. Scand. J. Gastroenterol. (2003) 38(9):991-995.
   PubMed Web of Science ®Google Scholar
• ALLISON MC, BURROUGHS AK, NOONE P, SUMMERFIELD JA: Biliary lavage with corticosteroids in primary sclerosing cholangitis. A clinical, cholangiographic and bacteriological study. J. Hepatol. (1986) 3(1):118-122.
   PubMed Web of Science ®Google Scholar
• VAN HOOGSTRATEN HJ, VLEGGAAR FP, BOLAND GJ et al.: Budesonide or prednisone in combination with ursodeoxycholic acid in primary sclerosing cholangitis: a randomized double-blind pilot study. Belgian-Dutch PSC Study Group. Am. J. Gastroenterol. (2000) 95(8):2015-2022.
   PubMed Web of Science ®Google Scholar
• CHEN W, GLUUD C: Glucocorticosteroids for primary sclerosing cholangitis. Cochrane Database Syst. Rev. (2004) 3:CD004036.
   PubMedGoogle Scholar
• KYOKANE K, ICHIHARA T, HORISAWA M et al.: Successful treatment of primary sclerosing cholangitis with cyclosporine and corticosteroid. Hepatogastroenterology (1994) 41(5):449-452.
   PubMed Web of Science ®Google Scholar
• SANDBORN WJ, WIESNER RH, TREMAINE WJ, LARUSSO NF: Ulcerative colitis disease activity following treatment of associated primary sclerosing cholangitis with cyclosporin. Gut (1993) 34(2):242-246.
   PubMed Web of Science ®Google Scholar
• VAN THIEL DH, CARROLL P, ABU-ELMAGD K et al.: Tacrolimus (FK 506), a treatment for primary sclerosing cholangitis: results of an open-label preliminary trial. Am. J. Gastroenterol. (1995) 90(3):455-459.
   PubMed Web of Science ®Google Scholar
• STERLING RK, SALVATORI JJ, LUKETIC VA et al.: A prospective, randomized-controlled pilot study of ursodeoxycholic acid combined with mycophenolate mofetil in the treatment of primary sclerosing cholangitis. Aliment. Pharmacol. Ther. (2004) 20(9):943-949.
   PubMed Web of Science ®Google Scholar
• TALWALKAR JA, ANGULO P, KEACH JC, PETZ JL, JORGENSEN RA, LINDOR KD: Mycophenolate mofetil for the treatment of primary biliary cirrhosis in patients with an incomplete response to ursodeoxycholic acid. J. Clin. Gastroenterol. (2005) 39(2):168-171.
   PubMed Web of Science ®Google Scholar
• OO YH, NEUBERGER J: Options for treatment of primary biliary cirrhosis. Drugs (2004) 64(20):2261-2271.
   PubMed Web of Science ®Google Scholar
• KAPLAN MM: The use of methotrexate, colchicine, and other immunomodulatory drugs in the treatment of primary biliary cirrhosis. Semin. Liver Dis. (1997) 17(2):129-136.
   PubMed Web of Science ®Google Scholar
• CARITHERS RL Jr: Primary biliary cirrhosis: specific treatment. Clin. Liver Dis. (2003) 7(4):923-939.
   PubMedGoogle Scholar
• LEUSCHNER M, GULDUTUNA S, YOU T, HUBNER K, BHATTI S, LEUSCHNER U: Ursodeoxycholic acid and prednisolone versus ursodeoxycholic acid and placebo in the treatment of early stages of primary biliary cirrhosis. J. Hepatol. (1996) 25(1):49-57.
   PubMed Web of Science ®Google Scholar
• RAUTIAINEN H, KARKKAINEN P, KARVONEN AL et al.: Budesonide combined with UDCA to improve liver histology in primary biliary cirrhosis: a three-year randomized trial. Hepatology (2005) 41(4):747-752.
   PubMed Web of Science ®Google Scholar
• LEUSCHNER M, MAIER KP, SCHLICHTING J et al.: Oral budesonide and ursodeoxycholic acid for treatment of primary biliary cirrhosis: results of a prospective double-blind trial. Gastroenterology (1999) 117(4):918-925.
   PubMed Web of Science ®Google Scholar
• ANGULO P, JORGENSEN RA, KEACH JC, DICKSON ER, SMITH C, LINDOR KD: Oral budesonide in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid. Hepatology (2000) 31(2):318-323.
   PubMed Web of Science ®Google Scholar
• HEMPFLING W, GRUNHAGE F, DILGER K, REICHEL C, BEUERS U, SAUERBRUCH T: Pharmacokinetics and pharmacodynamic action of budesonide in early- and late-stage primary biliary cirrhosis. Hepatology (2003) 38(1):196-202.
   PubMed Web of Science ®Google Scholar
• CHRISTENSEN E, NEUBERGER J, CROWE J et al.: Beneficial effect of azathioprine and prediction of prognosis in primary biliary cirrhosis. Final results of an international trial. Gastroenterology (1985) 89(5):1084-1091.
   PubMed Web of Science ®Google Scholar
• CROWE J, CHRISTENSEN E, SMITH M et al.: Azathioprine in primary biliary cirrhosis: a preliminary report of an international trial. Gastroenterology (1980) 78(5 Part 1):1005-1010.
   PubMed Web of Science ®Google Scholar
• WOLFHAGEN FH, VAN HOOGSTRATEN HJ, VAN BUUREN HR et al.: Triple therapy with ursodeoxycholic acid, prednisone and azathioprine in primary biliary cirrhosis: a 1-year randomized, placebo-controlled study. J. Hepatol. (1998) 29(5):736-742.
   PubMed Web of Science ®Google Scholar
• KAPLAN MM, CHENG S, PRICE LL, BONIS PA: A randomized controlled trial of colchicine plus ursodiol versus methotrexate plus ursodiol in primary biliary cirrhosis: ten-year results. Hepatology (2004) 39(4):915-923.
   PubMed Web of Science ®Google Scholar
• HENDRICKSE MT, RIGNEY E, GIAFFER MH et al.: Low-dose methotrexate is ineffective in primary biliary cirrhosis: long-term results of a placebo-controlled trial. Gastroenterology (1999) 117(2):400-407.
   PubMed Web of Science ®Google Scholar
• LOMBARD M, PORTMANN B, NEUBERGER J et al.: Cyclosporin A treatment in primary biliary cirrhosis: results of a long-term placebo controlled trial. Gastroenterology (1993) 104(2):519-526.
   PubMed Web of Science ®Google Scholar
• BEUKERS R, DE RAVE S, VAN DEN BERG JW, SCHALM SW: Oral pharmacokinetics of cyclosporin in patients with primary biliary cirrhosis and patients with skin diseases. Aliment. Pharmacol. Ther. (1992) 6(4):459-468.
   PubMed Web of Science ®Google Scholar
• NEUBERGER J, GUNSON B, HUBSCHER S, NIGHTINGALE P: Immunosuppression affects the rate of recurrent primary biliary cirrhosis after liver transplantation. Liver Transpl. (2004) 10(4):488-491.
   PubMed Web of Science ®Google Scholar
• SANCHEZ EQ, LEVY MF, GOLDSTEIN RM et al.: The changing clinical presentation of recurrent primary biliary cirrhosis after liver transplantation. Transplantation (2003) 76(11):1583-1588.
   Google Scholar
• LEVITSKY J, HART J, COHEN SM, TE HS: The effect of immunosuppressive regimens on the recurrence of primary biliary cirrhosis after liver transplantation. Liver Transpl. (2003) 9(7):733-736.
   PubMed Web of Science ®Google Scholar
• AGUILAR-BERNIER M, BASSAS-VILA J, SANZ-MUNOZ C, MIRANDA-ROMERO A: Successful treatment of pruritus with topical tacrolimus in a patient with primary biliary cirrhosis. Br. J. Dermatol. (2005) 152(4):808-809.
   PubMed Web of Science ®Google Scholar
• VERGANI D, MIELI-VERGANI G: Autoimmune hepatitis. Minerva Gastroenterol. Dietol. (2004) 50(2):113-123.
   PubMedGoogle Scholar
• AQEL BA, MACHICAO V, ROSSER B, SATYANARAYANA R, HARNOIS DM, DICKSON RC: Efficacy of tacrolimus in the treatment of steroid refractory autoimmune hepatitis. J. Clin. Gastroenterol. (2004) 38(9):805-809.
   PubMed Web of Science ®Google Scholar
• MEDINA J, GARCIA-BUEY L, MORENO-OTERO R: Review article: immunopathogenetic and therapeutic aspects of autoimmune hepatitis. Aliment. Pharmacol. Ther. (2003) 17(1):1-16.
   PubMedGoogle Scholar
• CZAJA AJ, BIANCHI FB, CARPENTER HA et al.: Treatment challenges and investigational opportunities in autoimmune hepatitis. Hepatology (2005) 41(1):207-215.
   PubMed Web of Science ®Google Scholar
• DE BOER NK, VAN NIEUWKERK CM, APARICIO PAGES MN, DE BOER SY, DERIJKS LJ, MULDER CJ: Promising treatment of autoimmune hepatitis with 6-thioguanine after adverse events on azathioprine. Eur. J. Gastroenterol. Hepatol. (2005) 17(4):457-461.
   PubMed Web of Science ®Google Scholar
• MALEKZADEH R, NASSERI-MOGHADDAM S, KAVIANI MJ, TAHERI H, KAMALIAN N, SOTOUDEH M: Cyclosporin A is a promising alternative to corticosteroids in autoimmune hepatitis. Dig. Dis. Sci. (2001) 46(6):1321-1327.
   PubMed Web of Science ®Google Scholar
• KERKAR N, DUGAN C, RUMBO C et al.: Rapamycin successfully treats post-transplant autoimmune hepatitis. Am. J. Transplant. (2005) 5(5):1085-1089.
   PubMed Web of Science ®Google Scholar